Artivion, Inc. (AORT)
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
- Symbol
- AORT
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $1.14B
- 52 week range
- 19.16 - 48.25
Valuation
- Share price
- $23.53 (close of 2026-09-23)
- P/E (TTM)
- -470.60x
- Price to book
- 2.56x
- Price to free cash flow
- -124.73x
- Enterprise value
- $1.47B
- Book value per share
- $9.18
Price performance
| Period | Change |
|---|
| 1 day | -0.42% |
| 5 days | -7.29% |
| 1 month | -16.20% |
| 3 months | +13.78% |
| 6 months | -34.13% |
| Year to date | -48.41% |
| 1 year | -42.75% |
| 3 years | +56.45% |
| 5 years | -0.63% |
| 10 years | +29.71% |
| All time | +488.25% |
Profitability and growth
- Return on equity
- 2.18%
- Return on invested capital
- 4.48%
- Return on assets
- 1.10%
- Return on capital employed
- 4.31%
- Gross margin
- 64.40%
- Net margin
- 2.21%
- EBITDA margin
- 12.73%
- Revenue growth
- 13.59%
- Net income growth
- 173.12%
- Free cash flow growth
- -92.41%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -0.80%
- Current ratio
- 3.47x
- Net debt to EBITDA
- 6.48x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $441.33M
- Cost of revenue
- $157.10M
- Gross profit
- $284.23M
- EBITDA
- $56.20M
- Net income
- $9.77M
- Earnings per share
- $0.22
- Research and development
- $30.99M
- Shares outstanding
- 45.34M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $441.33M | $284.23M | $9.77M | $0.22 |
| 2024-12-31 | $388.54M | $248.78M | $-13.36M | $-0.32 |
| 2023-12-31 | $354.00M | $229.18M | $-30.69M | $-0.75 |
| 2022-12-31 | $313.79M | $202.52M | $-19.19M | $-0.48 |
| 2021-12-31 | $298.84M | $197.51M | $-14.83M | $-0.38 |
| 2020-12-31 | $253.23M | $167.78M | $-16.68M | $-0.44 |
| 2019-12-31 | $276.22M | $183.01M | $1.72M | $0.05 |
| 2018-12-31 | $262.84M | $172.98M | $-2.84M | $-0.08 |
| 2017-12-31 | $189.70M | $128.64M | $3.70M | $0.11 |
| 2016-12-31 | $180.38M | $118.90M | $10.78M | $0.33 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 64.40% | 2.21% | 2.18% | 4.48% |
| 2024-12-31 | 64.03% | -3.44% | -4.84% | 5.65% |
| 2023-12-31 | 64.74% | -8.67% | -10.89% | 0.49% |
| 2022-12-31 | 64.54% | -6.12% | -6.75% | 0.52% |
| 2021-12-31 | 66.09% | -4.96% | -4.93% | 1.33% |
| 2020-12-31 | 66.26% | -6.59% | -5.07% | 0.42% |
| 2019-12-31 | 66.26% | 0.62% | 0.60% | 3.43% |
| 2018-12-31 | 65.81% | -1.08% | -1.03% | 2.04% |
| 2017-12-31 | 67.81% | 1.95% | 1.34% | 1.75% |
| 2016-12-31 | 65.92% | 5.98% | 5.16% | 6.34% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $64.91M | $215.11M |
| 2024-12-31 | $53.46M | $314.15M |
| 2023-12-31 | $58.94M | $305.53M |
| 2022-12-31 | $39.35M | $306.50M |
| 2021-12-31 | $55.01M | $307.49M |
| 2020-12-31 | $61.41M | $290.47M |
| 2019-12-31 | $33.77M | $214.57M |
| 2018-12-31 | $41.49M | $215.72M |
| 2017-12-31 | $39.98M | $218.24M |
| 2016-12-31 | $56.64M | $67.01M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $839.00K | $24.39M |
| 2024-12-31 | $11.05M | $14.24M |
| 2023-12-31 | $9.07M | $14.42M |
| 2022-12-31 | $-15.87M | $12.34M |
| 2021-12-31 | $-15.68M | $10.71M |
| 2020-12-31 | $5.04M | $6.91M |
| 2019-12-31 | $7.75M | $8.80M |
| 2018-12-31 | $4.09M | $6.33M |
| 2017-12-31 | $4.17M | $6.92M |
| 2016-12-31 | $13.52M | $6.33M |
Dividend history
- Most recent payment
- 2015-12-09
| Payment date | Dividend per share |
|---|
| 2015-12-09 | $0.03 |
| 2015-09-09 | $0.03 |
| 2015-06-10 | $0.03 |
| 2015-03-11 | $0.03 |
| 2014-12-10 | $0.03 |
| 2014-09-10 | $0.03 |
| 2014-06-11 | $0.03 |
| 2014-03-12 | $0.03 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $0.11
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.13 |
| 2026-05-07 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-05 | - | - |
| 2025-02-24 | - | - |
| 2025-02-13 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- artivion.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades